Award Expands Current Platforms to Improve DoD Counterfeit Risk
Mitigation
STONY BROOK, N.Y. -- (Business Wire)
Applied DNA Sciences, Inc. (“Applied DNA,” “the company,” NASDAQ:APDN),
a provider of DNA-based supply chain, anti-counterfeiting and anti-theft
technology, product genotyping and DNA mass production for diagnostics
and therapeutics, announced that it has been awarded a two-year,
approximately $1.5 million competitive-bid development contract. The
award, funded by the Office of the Secretary of Defense on behalf of the
Defense Logistics Agency (DLA), runs from June 1, 2017 to May 31 2019,
and was granted via a Rapid Innovation Fund (RIF) that provides DLA with
innovative technologies that can be rapidly inserted into acquisition
programs to meet specific defense needs. Management oversight for this
RIF contract will be from DLA HQ located in Fort Belvoir, Virginia.
Applied DNA is already contracted by DLA to supply the company’s
SigNature® DNA to protect the supply chains of high-risk FSC
5962 microcircuits that are frequently counterfeited leading to enhanced
risk of cyberattacks.
Dr. James Hayward, President and CEO of Applied DNA, stated: “Our
scalable platform for securing the supply chains of large commercial
ecosystems, using inalterable molecular 'certificates' and data capture
that can be assessed by permissioned partners, is perfectly suited to
keep systems as large and diverse as the US DoD secure from the risk of
malevolent copies.”
This firm-fixed price contract follows a prior RIF contract that enabled
Applied DNA to develop counterfeit mitigation technologies based upon
its proprietary DNA platforms, that protect plastics, silicone
elastomers, oils, bearings, fasteners and many other high-risk
commodities that are procured by DLA on behalf of DoD. This contract
will extend the company’s authentication platform to facilitate broader
use in protecting high-risk or mission-critical material purchased by
DLA.
Said Janice Meraglia, Vice President of Military and Government
Projects: “It is an honor to work with DLA as it embraces innovative
solutions to proactively address supply chain challenges. Our working
relationship with DoD and non-DoD federal agencies, as well as diverse
industry partners, provides us with unique insight for agile support.”
About Applied DNA Sciences
Applied DNA Sciences makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help protect
products, brands, entire supply chains, and intellectual property of
companies, governments and consumers from theft, counterfeiting, fraud
and diversion. The proprietary DNA-based “CertainT™” platform can be
used to identify, tag, track, and trace products, to help assure
authenticity, origin, traceability and quality of products. SigNature®
DNA describes the core technology ingredient that is at the heart
of a family of uncopyable, security and authentication solutions such as
SigNature® T and fiberTyping®, targeted toward
textiles and apparel, BackTrac™ and DNAnet®, for anti-theft
and loss prevention, and digitalDNA®, providing powerful
track- and-trace. All provide a forensic chain of evidence, and can be
used to prosecute perpetrators. Applied DNA Sciences is also engaged in
the large-scale production of specific DNA sequences using the
polymerase chain reaction.
Go to adnas.com for more information, events and to learn more about how
Applied DNA Sciences makes life real and safe. Common stock listed on
NASDAQ under the symbol APDN, and warrants are listed under the symbol
APDNW.
Forward-Looking Statements
The statements made by APDN in this press release may be
“forward-looking” in nature within the meaning of the Private Securities
Litigation Act of 1995. Forward-looking statements describe APDN’s
future plans, projections, strategies and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many of
which are beyond the control of APDN. Actual results could differ
materially from those projected due to our short operating history,
limited financial resources, limited market acceptance, market
competition and various other factors detailed from time to time in
APDN’s SEC reports and filings, including our Annual Report on Form 10-K
filed on December 6, 2016, and our subsequent quarterly reports on Form
10-Q filed on February 9, 2017, and May 11, 2017 which are available at www.sec.gov.
APDN undertakes no obligation to update publicly any forward-looking
statements to reflect new information, events or circumstances after the
date hereof to reflect the occurrence of unanticipated events, unless
otherwise required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170606005211/en/
Contacts:
For Applied DNA Sciences, Inc.
Investor Relations:
Sanjay Hurry
shurry@lha.com
or
Media:
Dian
Griesel Int’l.
Susan Forman, 212-825-3210
sforman@dgicomm.com
or
Program
Contact:
Janice Meraglia
janice.meraglia@adnas.com
web:
adnas.com
twitter: @APDN
Source: Applied DNA Sciences, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.